Ximelagatran or Warfarin for Stroke Prevention in Patients with Atrial Fibrillation?

Stroke

Volumn 35, Issue 2, 2004, Pages 389-391

  Hankey, Graeme J ^a,b   Klijn, Catharina J M ^a   Eikelboom, John W ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Advances in Stroke; Atrial fibrillation; Stroke prevention; Warfarin; Ximelagatran

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN; XIMELAGATRAN;

BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; DOSE RESPONSE; HEART ATRIUM FIBRILLATION; HEART RHYTHM; HUMAN; KIDNEY DISEASE; LIVER DISEASE; PRIORITY JOURNAL; PROPHYLAXIS; SHORT SURVEY; STROKE; TREATMENT PLANNING;

ANTICOAGULANTS; ATRIAL FIBRILLATION; AZETIDINES; BENZYLAMINES; CANADA; CEREBROVASCULAR ACCIDENT; DOUBLE-BLIND METHOD; HEMORRHAGE; HUMANS; RISK; THROMBIN; TREATMENT OUTCOME; UNITED STATES; VITAMIN K; WARFARIN;

EID: 0842289208     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000115528.53718.1B     Document Type: Short Survey

References (22)

1. Sandercock P, Bamford J, Dennis M, Burn J, Slattery J, Boonyakarnkul S, Warlow C. Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire Community Stroke Project). BMJ. 1992;305:1460-1465.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
3. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492-501.
4. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of anti platelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
5. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-1833.
6. van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJM, Tijssen JGP, Crijns HJGM, for the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-1840.
7. Reisman M, Gray W, Sievert H. An endovascular approach to stroke prevention in atrial fibrillation: results of the multicenter PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) feasibility trial. J Am Coll Cardiol. 2003;41:A301. Abstract.
8. Gillinov AM, Blackstone EH, McCarthy PM. Atrial fibrillation: current surgical options and their assessment. Ann Thorac Surg. 2002;74:2210-2217.
9. Van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288:2441-2448.
10. Furuya H, Fernandez-Salguero P, Gregory W, et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulant therapy. Pharmacogenetics. 1995;5:389-392.
11. Oldenburg J, Quenzel EM, Harbrecht U, et al. Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br J Haematol. 1997;98:240-244.
12. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119:8S-21S.
13. st century? Heart. 2003;89:553-554.
14. Peterson GM, Boom K, Jackson L, Vial JH. Doctor's beliefs on the use of antithrombotic therapy in atrial fibrillation: identifying barriers to stroke prevention. Intern Med J. 2002;32:15-23.
15. Kaplan KL, Francis CW. Direct thrombin inhibitors. Semin Hematol. 2002;39:187-196.
16. Bates SM, Weitz JI. Emerging anticoagulant drugs. Arterioscler Thromb Vasc Biol. 2003;23:1491-1500.
17. The Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of meta-analysis based on individual patient data. Lancet. 2002;359:294-302.
18. Halperin JL. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J. 2003;146:431-438.
19. Executive Steering Committee, on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet. 2003;362:1691-1698.
20. Halperin J, on behalf of the SPORTIF V Investigators. Efficacy and safety study of oral direct thrombin Inhibitor ximelagatran compared with dose-adjusted warfarin in the prevention of stroke and systemic embolic events in patients with atrial fibrillation (SPORTIF V). Presented at the American Heart Association Annual Scientific Meeting, Orlando, Florida, November 9-12, 2003.
21. Snapinn SM. Noninferiority trials. Curr Control Trials Cardiovasc Med. 2000;1:19-21.
22. Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, Nystrom P, Bylock A, for the ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet. 2003;362:789-797.